Breast Cancer With Low to Intermediate HER2 Expression
4 clinical trials · Condition
◉ Watch Breast Cancer With Low to Intermediate HER2 Expression
| Record | Firm | Date |
|---|---|---|
| Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence (NCT01479244) | Galena Biopharma, Inc. | 2011-11-01 |
Track Breast Cancer With Low to Intermediate HER2 Expression automatically
Every clearance here is in the API, with alerts when new ones post.